Incidence of prostate cancer in adolescents and young men is on the rise in most countries, with distant disease more common at diagnosis in these patients. (Cancer)
What’s the holdup on a cancer cure? Pharma’s focus on orphan drugs, the Washington Post writes.
Based on the CASSIOPEIA study, the FDA expanded the label for daratumumab (Darzalex) to include frontline treatment of transplant-eligible multiple myeloma, in combination with bortezomib (Velcade), thalidomide, and dexamethasone, Genmab announced.
GlaxoSmithKline, name-brand Zantac’s original developer, joined the expanding ranitidine recalls, pulling its versions from India and Hong Kong due to contamination with a potential carcinogen. (Bloomberg)
Is chronic insomnia in cancer survivors curable with a single sleep education class? Yes, say researchers from Dana-Farber Cancer Institute, though some patients may need more than one.
Retrospective data from MD Anderson Cancer Center backs up the ORATOR trial, showing that patients with early oropharyngeal cancer treated with primary radiation achieve swallowing outcomes similar to those seen with transoral robotic surgery. (JAMA Otolaryngology-Head & Neck Surgery)
News out of the American Association for Cancer Research’s health disparities conference found that:
Polling data from the American Society of Clinical Oncology found one in four adults believe e-cigarettes are harmless while nearly one-third believe the flavored versions are safer.
Frozen stem cells for dozens of childhood cancer patients at Children’s Hospital Los Angeles were lost following a freezer malfunction. (ABC7)
The New York Times offers its readers a crash course on pancreatic cancer and why it’s so difficult to prevent and treat.
FDA expanded the indication for Cologuard, the at-home stool DNA test for colorectal cancer, to include adults ages 45-49 in addition to those 50 or older, manufacturer Exact Sciences announced.
Meanwhile, Amgen reported positive results from two phase III studies on blinatumomab (Blincyto) for pediatric acute lymphoblastic leukemia in first relapse.
And UroGen touted its complete response data from OLYMPUS, a phase III trial testing mitomycin gel in low-grade bladder cancer.